Matches in Nanopublications for { ?s ?p "[Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP679871.RAZobDlQ0ZehwK1KxEJH9T-Fo7tZMrhydTwBJi8teUfco130_assertion description "[Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP679871.RAZobDlQ0ZehwK1KxEJH9T-Fo7tZMrhydTwBJi8teUfco130_provenance.
- NP258880.RATGptQBykTwPr6723PlS3HRkFpIHAMW-6uZvBmmP1uLk130_assertion description "[Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP258880.RATGptQBykTwPr6723PlS3HRkFpIHAMW-6uZvBmmP1uLk130_provenance.
- NP656551.RAIX9jT4YZ5U5WYtBjkWUo1d_5amim76yW_oDAzcz2V5k130_assertion description "[Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656551.RAIX9jT4YZ5U5WYtBjkWUo1d_5amim76yW_oDAzcz2V5k130_provenance.
- NP656553.RAPIlvpFrnSjRhKAtI8NNsp5ih3uz9P6rWR_Dw2F0Epps130_assertion description "[Thus, BAG-1 is unlikely to directly modulate PPARgamma function, but the overexpression of BAG-1 in some breast cancers may limit the efficacy of PPARgamma agonists as cancer therapies, by suppression of PPARgamma-induced cell death pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656553.RAPIlvpFrnSjRhKAtI8NNsp5ih3uz9P6rWR_Dw2F0Epps130_provenance.